Pregled bibliografske jedinice broj: 464392
Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years.
Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. // Annals of hematology, 88 (2009), 10; 1005-1013 doi:10.1007/s00277-009-0719-5 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 464392 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years.
Autori
Giebel, Sebastian ; Labopin, Myriam ; Holowiecki, Jerzy ; Labar, Boris ; Komarnicki, Mieczyslaw ; Koza, Vladimir ; Masszi, Tamas ; Mistrik, Martin ; Lange, Andrzej ; Hellmann, Andrzej ; Vitek, Antonin ; Pretnar, Joze ; Mayer, Jiri ; Rzepecki, Piotr ; Indrak, Karel ; Wiktor-Jedrzejczak, Wieslaw ; Wojnar, Jerzy ; Krawczyk-Kulis, Malgorzata ; Kyrcz-Krzemien, Slawomira ; Rocha, Vanderson
Izvornik
Annals of hematology (0939-5555) 88
(2009), 10;
1005-1013
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Matched related donor HSCT ; Acute leukemia ; Prognostic factors ; Leukemia-free survival ; Nonrelapse mortality
Sažetak
Abstract The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. Six hundred forty HSCT were performed between 1990 and 2006 for adults with acute myeloid (n = 459) and lymphoblastic (n = 181) leukemia. Two- year leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse incidence were 58 ± 2%, 19 ± 2%, and 23 ± 2%, respectively. The cumulative incidence of NRM decreased from 22 ± 2% for patients treated between 1990 and 2002 to 15 ± 3% for transplantations performed between 2003 and 2006 (p = 0.02), despite increasing recipient age. In a multivariate analysis, time of HSCT affected both NRM and LFS. Among other prognostic factors, the use of TBI decreased relapse incidence and increased the LFS rate. We conclude that results of MRD- HSCT for acute leukemia in Eastern Europe improved over time as a consequence of decreased NRM. The use of TBI containing regimens appears advantagous.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081872-1913 - LEUKEMIJE I TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA (Duraković, Nadira, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Boris Labar
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE